Arbutus to present at chardan's 6th annual genetic medicines conference

Warminster, pa., sept. 22, 2022 (globe newswire) -- arbutus biopharma corporation (nasdaq: abus), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that the company will participate in a fireside chat at chardan's 6th annual genetic medicines conference taking place in new york on tuesday, october 4, 2022 at 2:30 pm et.
ABUS Ratings Summary
ABUS Quant Ranking